{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:34:14Z","timestamp":1777566854627,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Acetyl-CoA acetyltransferase 2 (ACAT2) is a lipid metabolism enzyme and rarely was researched in epithelial ovarian cancer (EOC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>ACAT2 expressions were confirmed in two pairs of cell lines (A2780 and A2780\/DDP, OVCAR8 and OVCAR8\/DDP) from Gene Expression Omnibus database by bioinformatics analysis, and in A2780 and A2780\/DDP cell lines by quantitative real-time polymerase chain reaction and western blotting. Tissue samples were stained by immunohistochemistry and scored for ACAT2 expression. The relationships between ACAT2 expression and clinicopathological characteristics were analyzed by \u03c7<jats:sup>2<\/jats:sup> test. The prognosis of ACAT2 was analyzed by the log-rank tests and Cox regression models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ACAT2 was remarkably upregulated in the above drug-resistant cell lines by mRNA (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) and protein expression (<jats:italic>P<\/jats:italic>\u2009=\u20090.026) than those in sensitive ones. Patients were classified as ACAT2-high (n\u2009=\u200951) and ACAT2-low (n\u2009=\u200926) according to immunohistochemical score. ACAT2 expression had a significantly inverse correlation with FIGO stage (<jats:italic>P<\/jats:italic>\u2009=\u20090.030) and chemo-response (<jats:italic>P<\/jats:italic>\u2009=\u20090.041). A marginal statistical significance existed in ACAT2 expression and ascites volume (<jats:italic>P<\/jats:italic>\u2009=\u20090.092). Univariate analysis suggested that high-expressed ACAT2 was associated with decreased platinum-free interval (PFI) (8.57 vs. 14.13 months, <jats:italic>P<\/jats:italic>\u2009=\u20090.044), progression-free survival (PFS) (14.12 vs. 19.79 months, <jats:italic>P<\/jats:italic>\u2009=\u20090.039) and overall survival (OS) (36.89 vs. 52.40 months, <jats:italic>P<\/jats:italic>\u2009=\u20090.044). Multivariate analysis demonstrated that ACAT2 expression (hazard ratio\u2009=\u20092.18, 95% confidence interval: 1.15\u20134.11, <jats:italic>P<\/jats:italic>\u2009=\u20090.017) affected OS independently, rather than PFI and PFS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The expression of ACAT2 in A2780\/DDP and OVCAR8\/DDP was higher than the corresponding A2780 and OVCAR8. High-expressed ACAT2 was associated with advanced FIGO stage, chemo-resistance, and decreased PFI, PFS and OS. It was an independent prognostic factor of OS in EOC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13000-023-01435-4","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:03:02Z","timestamp":1704373382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Jinfeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadi","family":"Bin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"1435_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.omto.2021.02.012","volume":"20","author":"L Zhao","year":"2021","unstructured":"Zhao L, et al. A polygenic methylation prediction model associated with response to chemotherapy in epithelial Ovarian cancer. Mol Ther Oncolytics. 2021;20:545\u201355.","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"1435_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13148-018-0602-0","volume":"11","author":"S Moufarrij","year":"2019","unstructured":"Moufarrij S, et al. Epigenetic therapy for Ovarian cancer: promise and progress. Clin Epigenetics. 2019;11(1):7.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"1435_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/19336918.2020.1732761","volume":"14","author":"Z Tavsan","year":"2020","unstructured":"Tavsan Z, Kayali HA. EpCAM-claudin-tetraspanin-modulated Ovarian cancer progression and drug resistance. Cell Adh Migr. 2020;14(1):57\u201368.","journal-title":"Cell Adh Migr"},{"issue":"1","key":"1435_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13048-021-00884-z","volume":"14","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. TTK is a potential therapeutic target for cisplatin-resistant Ovarian cancer. J Ovarian Res. 2021;14(1):128.","journal-title":"J Ovarian Res"},{"key":"1435_CR5","doi-asserted-by":"crossref","unstructured":"Nowak M, Klink M. The role of Tumor-Associated macrophages in the Progression and Chemoresistance of Ovarian Cancer. Cells, 2020. 9(5).","DOI":"10.3390\/cells9051299"},{"issue":"3","key":"1435_CR6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.tjog.2012.07.003","volume":"51","author":"YT Chuang","year":"2012","unstructured":"Chuang YT, Chang CL. Extending platinum-free interval in partially platinum-sensitive recurrent Ovarian cancer by a non-platinum regimen: its possible clinical significance. Taiwan J Obstet Gynecol. 2012;51(3):336\u201341.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"1435_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.semcancer.2020.08.017","volume":"77","author":"O Le Saux","year":"2021","unstructured":"Le Saux O, Ray-Coquard I, Labidi-Galy SI. Challenges for immunotherapy for the treatment of platinum resistant Ovarian cancer. Semin Cancer Biol. 2021;77:127\u201343.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"1435_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299\u2013308.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1435_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent Ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080\u20137.","journal-title":"Ann Oncol"},{"issue":"34","key":"1435_CR10","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, et al. Safety and Antitumor activity of Anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant Ovarian Cancer. J Clin Oncol. 2015;33(34):4015\u201322.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1435_CR11","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1200\/JCO.19.02059","volume":"38","author":"D Zamarin","year":"2020","unstructured":"Zamarin D, et al. Randomized phase II trial of Nivolumab Versus Nivolumab and Ipilimumab for recurrent or persistent Ovarian Cancer: an NRG Oncology Study. J Clin Oncol. 2020;38(16):1814\u201323.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1435_CR12","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent Ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302\u20138.","journal-title":"J Clin Oncol"},{"issue":"7353","key":"1435_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research","year":"2011","unstructured":"Cancer Genome Atlas Research. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315.","journal-title":"Nature"},{"issue":"2","key":"1435_CR14","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.3802\/jgo.2021.32.e18","volume":"32","author":"HY Lu","year":"2021","unstructured":"Lu HY, et al. Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients. J Gynecol Oncol. 2021;32(2):e18.","journal-title":"J Gynecol Oncol"},{"key":"1435_CR15","doi-asserted-by":"publisher","first-page":"725264","DOI":"10.3389\/fonc.2021.725264","volume":"11","author":"H Zheng","year":"2021","unstructured":"Zheng H, et al. Construction and validation of a platinum sensitivity predictive model with multiple genomic variations for epithelial Ovarian Cancer. Front Oncol. 2021;11:725264.","journal-title":"Front Oncol"},{"issue":"10","key":"1435_CR16","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.7150\/jca.46621","volume":"12","author":"TT Gong","year":"2021","unstructured":"Gong TT, et al. Application of machine learning in prediction of Chemotherapy resistant of Ovarian Cancer based on gut microbiota. J Cancer. 2021;12(10):2877\u201385.","journal-title":"J Cancer"},{"issue":"14","key":"1435_CR17","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1158\/0008-5472.CAN-17-3746","volume":"78","author":"E Kozlowska","year":"2018","unstructured":"Kozlowska E, et al. Mathematical modeling predicts response to Chemotherapy and Drug combinations in Ovarian Cancer. Cancer Res. 2018;78(14):4036\u201344.","journal-title":"Cancer Res"},{"issue":"3","key":"1435_CR18","first-page":"201","volume":"102","author":"MM Mao","year":"2022","unstructured":"Mao MM, et al. [Prediction of platinum-based chemotherapy sensitivity for epithelial Ovarian cancer by multi-sequence MRI-based radiomic nomogram]. Zhonghua Yi Xue Za Zhi. 2022;102(3):201\u20138.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1435_CR19","doi-asserted-by":"crossref","unstructured":"Plotti F et al. Role of BRCA mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: a retrospective pilot study. Biomedicines, 2021. 9(1).","DOI":"10.3390\/biomedicines9010055"},{"key":"1435_CR20","doi-asserted-by":"publisher","first-page":"111013","DOI":"10.1016\/j.biopha.2020.111013","volume":"133","author":"X Yi","year":"2021","unstructured":"Yi X, et al. Incorporating SULF1 polymorphisms in a pretreatment CT-based radiomic model for predicting platinum resistance in Ovarian cancer treatment. Biomed Pharmacother. 2021;133:111013.","journal-title":"Biomed Pharmacother"},{"key":"1435_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.semcancer.2020.12.024","volume":"77","author":"A Ghoneum","year":"2021","unstructured":"Ghoneum A, et al. Exploring the clinical value of Tumor microenvironment in platinum-resistant Ovarian cancer. Semin Cancer Biol. 2021;77:83\u201398.","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"1435_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/15592294.2016.1241932","volume":"11","author":"G Greville","year":"2016","unstructured":"Greville G, et al. Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and Ovarian cancer. Epigenetics. 2016;11(12):845\u201357.","journal-title":"Epigenetics"},{"key":"1435_CR23","doi-asserted-by":"crossref","unstructured":"Wilczynski JR, Wilczynski M, Paradowska E. Cancer Stem cells in Ovarian Cancer-A source of Tumor Success and a Challenging Target for Novel therapies. Int J Mol Sci, 2022. 23(5).","DOI":"10.3390\/ijms23052496"},{"issue":"7","key":"1435_CR24","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1002\/cam4.1530","volume":"7","author":"MR Alves","year":"2018","unstructured":"Alves MR, et al. Downregulation of AGR2, p21, and cyclin D and alterations in p53 function were associated with Tumor progression and chemotherapy resistance in epithelial ovarian carcinoma. Cancer Med. 2018;7(7):3188\u201399.","journal-title":"Cancer Med"},{"issue":"43","key":"1435_CR25","doi-asserted-by":"publisher","first-page":"44938","DOI":"10.1074\/jbc.M408507200","volume":"279","author":"JJ Liang","year":"2004","unstructured":"Liang JJ, et al. Overexpression of human diacylglycerol acyltransferase 1, acyl-coa:cholesterol acyltransferase 1, or acyl-CoA:cholesterol acyltransferase 2 stimulates secretion of apolipoprotein B-containing lipoproteins in McA-RH7777 cells. J Biol Chem. 2004;279(43):44938\u201344.","journal-title":"J Biol Chem"},{"issue":"Pt 3","key":"1435_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1042\/BJ20051417","volume":"394","author":"BL Song","year":"2006","unstructured":"Song BL, et al. Human acyl-CoA:cholesterol acyltransferase 2 gene expression in intestinal Caco-2 cells and in hepatocellular carcinoma. Biochem J. 2006;394(Pt 3):617\u201326.","journal-title":"Biochem J"},{"issue":"4","key":"1435_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10863-021-09901-8","volume":"53","author":"L Cheng","year":"2021","unstructured":"Cheng L, et al. Circ_RPL23A acts as a miR-1233 sponge to suppress the progression of clear cell renal cell carcinoma by promoting ACAT2. J Bioenerg Biomembr. 2021;53(4):415\u201328.","journal-title":"J Bioenerg Biomembr"},{"key":"1435_CR28","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.2147\/OTT.S238973","volume":"13","author":"M Weng","year":"2020","unstructured":"Weng M, et al. ACAT2 promotes cell proliferation and Associates with malignant progression in Colorectal Cancer. Onco Targets Ther. 2020;13:3477\u201388.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"1435_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s13402-017-0342-8","volume":"40","author":"Y Huang","year":"2017","unstructured":"Huang Y, et al. Leptin promotes the migration and invasion of Breast cancer cells by upregulating ACAT2. Cell Oncol (Dordr). 2017;40(6):537\u201347.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"1435_CR30","doi-asserted-by":"publisher","first-page":"e0228024","DOI":"10.1371\/journal.pone.0228024","volume":"15","author":"VN Ayyagari","year":"2020","unstructured":"Ayyagari VN, et al. Assessment of acyl-CoA cholesterol acyltransferase (ACAT-1) role in Ovarian cancer progression-An in vitro study. PLoS ONE. 2020;15(1):e0228024.","journal-title":"PLoS ONE"},{"issue":"3","key":"1435_CR31","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ygyno.2022.01.010","volume":"164","author":"J Zhang","year":"2022","unstructured":"Zhang J, et al. Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in Ovarian cancer. Gynecol Oncol. 2022;164(3):566\u201376.","journal-title":"Gynecol Oncol"},{"key":"1435_CR32","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.2147\/OTT.S336190","volume":"14","author":"Erratum","year":"2021","unstructured":"Erratum. ACAT2 promotes cell proliferation and Associates with malignant progression in Colorectal Cancer [Corrigendum]. Onco Targets Ther. 2021;14:4641\u20133.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"1435_CR33","doi-asserted-by":"publisher","first-page":"8121","DOI":"10.1007\/s13277-015-4720-4","volume":"37","author":"Z Zhao","year":"2016","unstructured":"Zhao Z, et al. Prognostic significance of two lipid metabolism enzymes, HADHA and ACAT2, in clear cell renal cell carcinoma. Tumour Biol. 2016;37(6):8121\u201330.","journal-title":"Tumour Biol"},{"issue":"4","key":"1435_CR34","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3892\/ol.2021.12994","volume":"22","author":"D Ikoma","year":"2021","unstructured":"Ikoma D, et al. A nuclear polymorphism at the 8q24 region is associated with improved survival time and chemo-response in high-grade serous Ovarian cancer. Oncol Lett. 2021;22(4):733.","journal-title":"Oncol Lett"},{"issue":"1","key":"1435_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-016-0548-9","volume":"15","author":"J Gonzalez Bosquet","year":"2016","unstructured":"Gonzalez Bosquet J, et al. Prediction of chemo-response in serous Ovarian cancer. Mol Cancer. 2016;15(1):66.","journal-title":"Mol Cancer"},{"issue":"6","key":"1435_CR36","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/bjc.2014.385","volume":"111","author":"JJ Souchek","year":"2014","unstructured":"Souchek JJ, et al. Unbiased analysis of Pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation. Br J Cancer. 2014;111(6):1139\u201349.","journal-title":"Br J Cancer"},{"issue":"6","key":"1435_CR37","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1161\/01.ATV.0000166548.65753.1e","volume":"25","author":"LL Rudel","year":"2005","unstructured":"Rudel LL, Lee RG, Parini P. ACAT2 is a target for treatment of coronary Heart Disease associated with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2005;25(6):1112\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"18","key":"1435_CR38","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1002\/pmic.200900126","volume":"9","author":"EJ Davison","year":"2009","unstructured":"Davison EJ, et al. Proteomic analysis of increased parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function. Proteomics. 2009;9(18):4284\u201397.","journal-title":"Proteomics"},{"issue":"1","key":"1435_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.canlet.2013.05.004","volume":"336","author":"L Yang","year":"2013","unstructured":"Yang L, et al. Inhibition of mortalin expression reverses cisplatin resistance and attenuates growth of Ovarian cancer cells. Cancer Lett. 2013;336(1):213\u201321.","journal-title":"Cancer Lett"},{"key":"1435_CR40","doi-asserted-by":"crossref","unstructured":"Hou S et al. PCDHGB7 Increases Chemosensitivity to Carboplatin by Inhibiting HSPA9 via Inducing Apoptosis in Breast Cancer Dis Markers, 2019. 2019: p.\u00a06131548.","DOI":"10.1155\/2019\/6131548"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-023-01435-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-023-01435-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-023-01435-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:05:16Z","timestamp":1704373516000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-023-01435-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1435"],"URL":"https:\/\/doi.org\/10.1186\/s13000-023-01435-4","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"21 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the First Affiliated Hospital of Xi\u2019an Jiaotong University (No. XJTU1AF2022LSK-182).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors participate in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors agree to publish this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}